Australia · Delayed Price · Currency is AUD Biome Australia Earnings Call Transcripts
Fiscal Year 2026
-
Record H1 2026 revenue and profit growth driven by premium practitioner-only model, strong gross margins, and expanding distribution. International expansion and proprietary clinical pipeline support long-term growth, with disciplined capital management and no retail price increases since 2019.
-
Record Q1 FY 2026 with $24M annualized sales, $462K EBITDA, and 84% YoY cash receipts growth. International expansion in Canada, Ireland, and New Zealand is accelerating, while gross margin remains above 61% and new product launches drive further growth.
Fiscal Year 2025
-
Record attendance marked a year of strong growth, with sales up 41% and net profit achieved. Key resolutions on remuneration, director re-election, share issues, and expansion plans were passed. International growth and new product launches position the company for continued success.
-
FY 2025 saw record revenue, strong EBITDA, and rapid distribution growth, with new product launches and international expansion driving performance. Vision 2027 targets remain on track, supported by innovation, premium positioning, and scalable global strategy.
-
Record growth and profitability are expected for FY25, with product innovation and international expansion driving momentum. Manufacturing flexibility and a growing institutional investor base support long-term strategic goals.
-
Achieved first net profit in H1 FY2025 with strong revenue growth, improved gross margins, and expanding distribution. International markets, especially Canada, are showing promising early results, and new product launches are planned for late FY2025.
Fiscal Year 2024
-
The meeting reviewed strong FY24 financial growth, approved key resolutions, and outlined a three-year strategic plan targeting AUD 75–85 million in cumulative sales. Expansion in international markets and new product development were highlighted, with a focus on premium, practitioner-only distribution.